Regional and disease-specific glycosaminoglycan composition and function in decellularized human lung extracellular matrix.
COPD
Decellularization
Extracellular matrix gel
Glycosaminoglycan
Lung
Matrix-associated growth factors
Journal
Acta biomaterialia
ISSN: 1878-7568
Titre abrégé: Acta Biomater
Pays: England
ID NLM: 101233144
Informations de publication
Date de publication:
15 09 2023
15 09 2023
Historique:
received:
24
02
2023
revised:
16
06
2023
accepted:
28
06
2023
pmc-release:
15
09
2024
medline:
22
8
2023
pubmed:
12
7
2023
entrez:
11
7
2023
Statut:
ppublish
Résumé
Decellularized lung scaffolds and hydrogels are increasingly being utilized in ex vivo lung bioengineering. However, the lung is a regionally heterogenous organ with proximal and distal airway and vascular compartments of different structures and functions that may be altered as part of disease pathogenesis. We previously described decellularized normal whole human lung extracellular matrix (ECM) glycosaminoglycan (GAG) composition and functional ability to bind matrix-associated growth factors. We now determine differential GAG composition and function in airway, vascular, and alveolar-enriched regions of decellularized lungs obtained from normal, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF) patients. Significant differences were observed in heparan sulfate (HS), chondroitin sulfate (CS), and hyaluronic acid (HA) content and CS/HS compositions between both different lung regions and between normal and diseased lungs. Surface plasmon resonance demonstrated that HS and CS from decellularized normal and COPD lungs similarly bound fibroblast growth factor 2, but that binding was decreased in decellularized IPF lungs. Binding of transforming growth factor β to CS was similar in all three groups but binding to HS was decreased in IPF compared to normal and COPD lungs. In addition, cytokines dissociate faster from the IPF GAGs than their counterparts. The differences in cytokine binding features of IPF GAGs may result from different disaccharide compositions. The purified HS from IPF lung is less sulfated than that from other lungs, and the CS from IPF contains more 6-O-sulfated disaccharide. These observations provide further information for understanding functional roles of ECM GAGs in lung function and disease. STATEMENT OF SIGNIFICANCE: Lung transplantation remains limited due to donor organ availability and need for life-long immunosuppressive medication. One solution, the ex vivo bioengineering of lungs via de- and recellularization has not yet led to a fully functional organ. Notably, the role of glycosaminoglycans (GAGs) remaining in decellularized lung scaffolds is poorly understood despite their important effects on cell behaviors. We have previously investigated residual GAG content of native and decellularized lungs and their respective functionality, and role during scaffold recellularization. We now present a detailed characterization of GAG and GAG chain content and function in different anatomical regions of normal diseased human lungs. These are novel and important observations that further expand knowledge about functional GAG roles in lung biology and disease.
Identifiants
pubmed: 37433361
pii: S1742-7061(23)00375-6
doi: 10.1016/j.actbio.2023.06.043
pmc: PMC10528722
mid: NIHMS1918501
pii:
doi:
Substances chimiques
Glycosaminoglycans
0
Chondroitin Sulfates
9007-28-7
Disaccharides
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
388-399Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL127144
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI156573
Pays : United States
Organisme : NIH HHS
ID : S10 OD028523
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL076122
Pays : United States
Informations de copyright
Copyright © 2023. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest This manuscript has not been published and is not under consideration for publication elsewhere. We have no conflicts of interest to disclose.
Références
Biomaterials. 2014 Mar;35(10):3281-97
pubmed: 24461327
Sci Rep. 2017 Apr 26;7(1):1210
pubmed: 28446792
J Struct Biol. 2013 Mar;181(3):264-73
pubmed: 23270863
Acta Biomater. 2020 Jan 15;102:231-246
pubmed: 31751810
Sci Rep. 2018 Feb 22;8(1):3502
pubmed: 29472603
Biomaterials. 2017 Sep;140:212-219
pubmed: 28662401
Stem Cell Reports. 2015 Mar 10;4(3):419-30
pubmed: 25660407
Biomaterials. 2013 Apr;34(13):3256-69
pubmed: 23384794
ACS Chem Biol. 2015 May 15;10(5):1303-10
pubmed: 25680304
Biochemistry. 2013 Dec 17;52(50):9009-19
pubmed: 24289246
Proteomics. 2008 Apr;8(7):1384-97
pubmed: 18318007
Acc Chem Res. 2004 Jul;37(7):431-8
pubmed: 15260505
Tissue Eng Part C Methods. 2012 Jun;18(6):420-32
pubmed: 22165818
Cell Stem Cell. 2018 Mar 1;22(3):302-305
pubmed: 29499149
Am J Respir Cell Mol Biol. 1993 Mar;8(3):245-51
pubmed: 8448015
Am J Physiol Lung Cell Mol Physiol. 2007 Jun;292(6):L1352-60
pubmed: 17307814
Matrix Biol. 2018 Nov;73:77-104
pubmed: 29524630
Methods Mol Biol. 2017;1627:253-283
pubmed: 28836208
Genes Dev. 2008 Oct 1;22(19):2645-50
pubmed: 18832069
Annu Rev Biomed Eng. 2017 Jun 21;19:1-26
pubmed: 28226217
PLoS One. 2016 Mar 08;11(3):e0150966
pubmed: 26954258
J Biol Chem. 2014 Apr 4;289(14):9754-65
pubmed: 24563485
J Biol Chem. 2017 Feb 10;292(6):2495-2509
pubmed: 28031461
Biomaterials. 2023 Feb;293:121960
pubmed: 36580718
Am J Respir Crit Care Med. 2012 Nov 1;186(9):866-76
pubmed: 22936357
Nat Protoc. 2014 Mar;9(3):541-58
pubmed: 24504479
J Biol Chem. 2008 Feb 29;283(9):5235-48
pubmed: 18156180
Acta Biomater. 2016 Dec;46:91-100
pubmed: 27693690
Semin Arthritis Rheum. 2001 Aug;31(1):58-68
pubmed: 11503140
J Biol Chem. 2002 Aug 9;277(32):28554-63
pubmed: 12034712
Int J Biochem Cell Biol. 2017 Feb;83:27-38
pubmed: 27974233
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679607
Am J Physiol Lung Cell Mol Physiol. 2014 Jul 1;307(1):L94-105
pubmed: 24748602
Biosensors (Basel). 2015 Jul 23;5(3):500-12
pubmed: 26213979